We are live on ! Find out more
DC

Decheng Capital Portfolio holdings

AUM $661M
1-Year Est. Return 299.97%
This Fund
S&P 500
This Quarter Est. Return
+11.95%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$422M
AUM Growth
+$95.9M
Cap. Flow
+$72.2M
Cap. Flow %
17.11%
Top 10 Hldgs %
87.52%
Holding
26
New
2
Increased
10
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$58M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$5.59M
3
NAMS icon
NewAmsterdam Pharma
NAMS
+$3.29M
4
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$1.94M
5
ACLX
Arcellx
ACLX
+$1.33M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$1.73M
2
GRAL
GRAIL Inc
GRAL
+$128K

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB.WS
26
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$63.2K 0.02%
646,057
– –
1
2

Similar funds

FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $661M AUM 14.84% 1-Year Est. Return
RCG
Regatta Capital Group El Segundo, California $661M AUM 17.85% 1-Year Est. Return
FM
Freemont Management Vaud, Switzerland $661M AUM 60.48% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
AWA
Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return
UCMOK
United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return

Decheng Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Decheng Capital held 26 positions worth $422M, up 29% from $326M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Decheng Capital deployed $72.2M of net new capital in Q3 2024, opening 2 new positions and adding to 10 existing holdings. Its largest new stake was Longboard Pharmaceuticals, Inc. Common Stock: 56,350 shares worth $1.88M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Illumina, an estimated $1.73M trimmed.

  • Decheng Capital's largest Q3 2024 buy was Longboard Pharmaceuticals, Inc. Common Stock: 56,350 shares worth $1.88M.
  • Decheng Capital added most to Nuvation Bio in Q3 2024, an estimated $58M increase.
  • Decheng Capital's biggest Q3 2024 reduction was Illumina, cutting an estimated $1.73M.
  • Decheng Capital's ten largest holdings make up 88% of its $422M portfolio in Q3 2024.
  • Decheng Capital opened 2 new positions and closed 0 in Q3 2024.
  • Decheng Capital's portfolio value rose 29% quarter-over-quarter to $422M.

Based on Decheng Capital's 13F filing for Q3 2024, filed 15 Nov 2024.